nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilutamide—AR—Medroxyprogesterone Acetate—uterine cancer	0.28	0.342	CbGbCtD
Nilutamide—AR—Progesterone—uterine cancer	0.185	0.227	CbGbCtD
Nilutamide—POR—Doxorubicin—uterine cancer	0.128	0.157	CbGbCtD
Nilutamide—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0612	0.0749	CbGbCtD
Nilutamide—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0427	0.0522	CbGbCtD
Nilutamide—CYP2C8—Progesterone—uterine cancer	0.0405	0.0496	CbGbCtD
Nilutamide—CYP2C19—Progesterone—uterine cancer	0.034	0.0416	CbGbCtD
Nilutamide—CYP2C9—Progesterone—uterine cancer	0.0283	0.0346	CbGbCtD
Nilutamide—CYP2C8—Etoposide—uterine cancer	0.0181	0.0222	CbGbCtD
Nilutamide—AR—semen—uterine cancer	0.00675	0.151	CbGeAlD
Nilutamide—AR—oviduct—uterine cancer	0.00495	0.111	CbGeAlD
Nilutamide—POR—myometrium—uterine cancer	0.00268	0.0602	CbGeAlD
Nilutamide—POR—uterine cervix—uterine cancer	0.00209	0.0468	CbGeAlD
Nilutamide—POR—decidua—uterine cancer	0.00199	0.0446	CbGeAlD
Nilutamide—POR—endometrium—uterine cancer	0.00189	0.0423	CbGeAlD
Nilutamide—POR—mammalian vulva—uterine cancer	0.00182	0.041	CbGeAlD
Nilutamide—AR—myometrium—uterine cancer	0.00158	0.0356	CbGeAlD
Nilutamide—POR—female gonad—uterine cancer	0.00142	0.0319	CbGeAlD
Nilutamide—POR—vagina—uterine cancer	0.00141	0.0317	CbGeAlD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.00137	0.0836	CbGpPWpGaD
Nilutamide—AR—epithelium—uterine cancer	0.00124	0.0279	CbGeAlD
Nilutamide—AR—uterine cervix—uterine cancer	0.00123	0.0277	CbGeAlD
Nilutamide—AR—smooth muscle tissue—uterine cancer	0.0012	0.0269	CbGeAlD
Nilutamide—AR—decidua—uterine cancer	0.00117	0.0264	CbGeAlD
Nilutamide—AR—renal system—uterine cancer	0.00115	0.0259	CbGeAlD
Nilutamide—AR—endometrium—uterine cancer	0.00111	0.025	CbGeAlD
Nilutamide—AR—mammalian vulva—uterine cancer	0.00108	0.0242	CbGeAlD
Nilutamide—AR—uterus—uterine cancer	0.00103	0.0231	CbGeAlD
Nilutamide—POR—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.00101	0.0615	CbGpPWpGaD
Nilutamide—CYP2C8—renal system—uterine cancer	0.000932	0.0209	CbGeAlD
Nilutamide—AR—female reproductive system—uterine cancer	0.000923	0.0207	CbGeAlD
Nilutamide—POR—lymph node—uterine cancer	0.000914	0.0205	CbGeAlD
Nilutamide—CYP2C8—endometrium—uterine cancer	0.000901	0.0202	CbGeAlD
Nilutamide—AR—female gonad—uterine cancer	0.00084	0.0189	CbGeAlD
Nilutamide—AR—vagina—uterine cancer	0.000835	0.0187	CbGeAlD
Nilutamide—AR—Coregulation of Androgen receptor activity—PAWR—uterine cancer	0.000801	0.0488	CbGpPWpGaD
Nilutamide—CYP2C19—vagina—uterine cancer	0.000774	0.0174	CbGeAlD
Nilutamide—CYP2C8—female reproductive system—uterine cancer	0.000747	0.0168	CbGeAlD
Nilutamide—CYP2C8—vagina—uterine cancer	0.000675	0.0152	CbGeAlD
Nilutamide—CYP2C9—female reproductive system—uterine cancer	0.000663	0.0149	CbGeAlD
Nilutamide—AR—lymph node—uterine cancer	0.00054	0.0121	CbGeAlD
Nilutamide—Hyperhidrosis—Progesterone—uterine cancer	0.000481	0.00395	CcSEcCtD
Nilutamide—Anorexia—Progesterone—uterine cancer	0.000474	0.0039	CcSEcCtD
Nilutamide—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.00047	0.00386	CcSEcCtD
Nilutamide—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.000464	0.00382	CcSEcCtD
Nilutamide—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00046	0.00378	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Etoposide—uterine cancer	0.000456	0.00375	CcSEcCtD
Nilutamide—Oedema—Medroxyprogesterone Acetate—uterine cancer	0.000451	0.0037	CcSEcCtD
Nilutamide—Insomnia—Progesterone—uterine cancer	0.00045	0.0037	CcSEcCtD
Nilutamide—Paraesthesia—Progesterone—uterine cancer	0.000446	0.00367	CcSEcCtD
Nilutamide—Dyspnoea—Progesterone—uterine cancer	0.000443	0.00364	CcSEcCtD
Nilutamide—Shock—Medroxyprogesterone Acetate—uterine cancer	0.000443	0.00364	CcSEcCtD
Nilutamide—Dyspepsia—Progesterone—uterine cancer	0.000438	0.0036	CcSEcCtD
Nilutamide—Alopecia—Dactinomycin—uterine cancer	0.000437	0.00359	CcSEcCtD
Nilutamide—Cough increased—Epirubicin—uterine cancer	0.000437	0.00359	CcSEcCtD
Nilutamide—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000436	0.00358	CcSEcCtD
Nilutamide—Decreased appetite—Progesterone—uterine cancer	0.000432	0.00355	CcSEcCtD
Nilutamide—Nocturia—Epirubicin—uterine cancer	0.000431	0.00354	CcSEcCtD
Nilutamide—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000429	0.00353	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Progesterone—uterine cancer	0.000429	0.00353	CcSEcCtD
Nilutamide—Constipation—Progesterone—uterine cancer	0.000425	0.00349	CcSEcCtD
Nilutamide—Pain—Progesterone—uterine cancer	0.000425	0.00349	CcSEcCtD
Nilutamide—Creatinine increased—Epirubicin—uterine cancer	0.00042	0.00345	CcSEcCtD
Nilutamide—Bone pain—Epirubicin—uterine cancer	0.000417	0.00343	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—PGR—uterine cancer	0.000415	0.0253	CbGpPWpGaD
Nilutamide—Feeling abnormal—Progesterone—uterine cancer	0.00041	0.00337	CcSEcCtD
Nilutamide—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000408	0.00335	CcSEcCtD
Nilutamide—Gastrointestinal pain—Progesterone—uterine cancer	0.000407	0.00334	CcSEcCtD
Nilutamide—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.000405	0.00333	CcSEcCtD
Nilutamide—Cough increased—Doxorubicin—uterine cancer	0.000404	0.00332	CcSEcCtD
Nilutamide—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000402	0.0033	CcSEcCtD
Nilutamide—Pneumonia—Etoposide—uterine cancer	0.000401	0.0033	CcSEcCtD
Nilutamide—Phosphatase alkaline increased—Epirubicin—uterine cancer	0.0004	0.00328	CcSEcCtD
Nilutamide—Ill-defined disorder—Dactinomycin—uterine cancer	0.0004	0.00328	CcSEcCtD
Nilutamide—Nocturia—Doxorubicin—uterine cancer	0.000399	0.00328	CcSEcCtD
Nilutamide—Anaemia—Dactinomycin—uterine cancer	0.000398	0.00327	CcSEcCtD
Nilutamide—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.000397	0.00326	CcSEcCtD
Nilutamide—Abdominal pain—Progesterone—uterine cancer	0.000393	0.00323	CcSEcCtD
Nilutamide—Body temperature increased—Progesterone—uterine cancer	0.000393	0.00323	CcSEcCtD
Nilutamide—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000392	0.00322	CcSEcCtD
Nilutamide—Melaena—Epirubicin—uterine cancer	0.00039	0.00321	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.000389	0.0032	CcSEcCtD
Nilutamide—Creatinine increased—Doxorubicin—uterine cancer	0.000388	0.00319	CcSEcCtD
Nilutamide—Malaise—Dactinomycin—uterine cancer	0.000388	0.00319	CcSEcCtD
Nilutamide—Bone pain—Doxorubicin—uterine cancer	0.000386	0.00317	CcSEcCtD
Nilutamide—Leukopenia—Dactinomycin—uterine cancer	0.000385	0.00317	CcSEcCtD
Nilutamide—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000385	0.00317	CcSEcCtD
Nilutamide—Blood urea increased—Epirubicin—uterine cancer	0.000377	0.0031	CcSEcCtD
Nilutamide—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000371	0.00305	CcSEcCtD
Nilutamide—Phosphatase alkaline increased—Doxorubicin—uterine cancer	0.00037	0.00304	CcSEcCtD
Nilutamide—Gastrointestinal pain—Medroxyprogesterone Acetate—uterine cancer	0.000368	0.00303	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—ESR2—uterine cancer	0.000366	0.0223	CbGpPWpGaD
Nilutamide—Discomfort—Dactinomycin—uterine cancer	0.000362	0.00298	CcSEcCtD
Nilutamide—Melaena—Doxorubicin—uterine cancer	0.000361	0.00297	CcSEcCtD
Nilutamide—Asthenia—Progesterone—uterine cancer	0.000357	0.00293	CcSEcCtD
Nilutamide—Hypoaesthesia—Etoposide—uterine cancer	0.000356	0.00293	CcSEcCtD
Nilutamide—Abdominal pain—Medroxyprogesterone Acetate—uterine cancer	0.000356	0.00293	CcSEcCtD
Nilutamide—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000356	0.00293	CcSEcCtD
Nilutamide—Urinary tract disorder—Etoposide—uterine cancer	0.000354	0.00291	CcSEcCtD
Nilutamide—Pruritus—Progesterone—uterine cancer	0.000352	0.00289	CcSEcCtD
Nilutamide—Oedema—Dactinomycin—uterine cancer	0.000351	0.00289	CcSEcCtD
Nilutamide—Urethral disorder—Etoposide—uterine cancer	0.000351	0.00288	CcSEcCtD
Nilutamide—Blood urea increased—Doxorubicin—uterine cancer	0.000349	0.00287	CcSEcCtD
Nilutamide—Abnormal vision—Epirubicin—uterine cancer	0.000349	0.00286	CcSEcCtD
Nilutamide—Diarrhoea—Progesterone—uterine cancer	0.00034	0.0028	CcSEcCtD
Nilutamide—Anorexia—Dactinomycin—uterine cancer	0.000335	0.00275	CcSEcCtD
Nilutamide—Blood alkaline phosphatase increased—Epirubicin—uterine cancer	0.000334	0.00274	CcSEcCtD
Nilutamide—Dizziness—Progesterone—uterine cancer	0.000329	0.0027	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.000328	0.02	CbGpPWpGaD
Nilutamide—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000323	0.00266	CcSEcCtD
Nilutamide—Abnormal vision—Doxorubicin—uterine cancer	0.000322	0.00265	CcSEcCtD
Nilutamide—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000319	0.00262	CcSEcCtD
Nilutamide—Alopecia—Etoposide—uterine cancer	0.000316	0.0026	CcSEcCtD
Nilutamide—Vomiting—Progesterone—uterine cancer	0.000316	0.0026	CcSEcCtD
Nilutamide—Rash—Progesterone—uterine cancer	0.000314	0.00258	CcSEcCtD
Nilutamide—Dermatitis—Progesterone—uterine cancer	0.000313	0.00257	CcSEcCtD
Nilutamide—Headache—Progesterone—uterine cancer	0.000311	0.00256	CcSEcCtD
Nilutamide—Hot flush—Epirubicin—uterine cancer	0.00031	0.00255	CcSEcCtD
Nilutamide—Blood alkaline phosphatase increased—Doxorubicin—uterine cancer	0.000309	0.00254	CcSEcCtD
Nilutamide—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000308	0.00253	CcSEcCtD
Nilutamide—Menopausal symptoms—Epirubicin—uterine cancer	0.000307	0.00253	CcSEcCtD
Nilutamide—Decreased appetite—Dactinomycin—uterine cancer	0.000305	0.00251	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000302	0.0184	CbGpPWpGaD
Nilutamide—Back pain—Etoposide—uterine cancer	0.000301	0.00248	CcSEcCtD
Nilutamide—Pain—Dactinomycin—uterine cancer	0.000301	0.00247	CcSEcCtD
Nilutamide—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.000298	0.00245	CcSEcCtD
Nilutamide—Cardiac failure—Epirubicin—uterine cancer	0.000297	0.00244	CcSEcCtD
Nilutamide—Nausea—Progesterone—uterine cancer	0.000295	0.00243	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Epirubicin—uterine cancer	0.00029	0.00238	CcSEcCtD
Nilutamide—Feeling abnormal—Dactinomycin—uterine cancer	0.00029	0.00238	CcSEcCtD
Nilutamide—Ill-defined disorder—Etoposide—uterine cancer	0.000289	0.00238	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.000289	0.0176	CbGpPWpGaD
Nilutamide—Anaemia—Etoposide—uterine cancer	0.000288	0.00237	CcSEcCtD
Nilutamide—Gastrointestinal pain—Dactinomycin—uterine cancer	0.000287	0.00236	CcSEcCtD
Nilutamide—Hot flush—Doxorubicin—uterine cancer	0.000287	0.00236	CcSEcCtD
Nilutamide—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000286	0.00235	CcSEcCtD
Nilutamide—Menopausal symptoms—Doxorubicin—uterine cancer	0.000284	0.00234	CcSEcCtD
Nilutamide—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000284	0.00233	CcSEcCtD
Nilutamide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000284	0.00233	CcSEcCtD
Nilutamide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000282	0.00232	CcSEcCtD
Nilutamide—Malaise—Etoposide—uterine cancer	0.000281	0.00231	CcSEcCtD
Nilutamide—Leukopenia—Etoposide—uterine cancer	0.000279	0.00229	CcSEcCtD
Nilutamide—Abdominal pain—Dactinomycin—uterine cancer	0.000278	0.00228	CcSEcCtD
Nilutamide—Body temperature increased—Dactinomycin—uterine cancer	0.000278	0.00228	CcSEcCtD
Nilutamide—Cardiac failure—Doxorubicin—uterine cancer	0.000275	0.00226	CcSEcCtD
Nilutamide—Loss of consciousness—Etoposide—uterine cancer	0.000274	0.00225	CcSEcCtD
Nilutamide—Cough—Etoposide—uterine cancer	0.000272	0.00224	CcSEcCtD
Nilutamide—Blood creatinine increased—Epirubicin—uterine cancer	0.000272	0.00223	CcSEcCtD
Nilutamide—Hypertension—Etoposide—uterine cancer	0.000269	0.00221	CcSEcCtD
Nilutamide—Gastrointestinal haemorrhage—Doxorubicin—uterine cancer	0.000268	0.00221	CcSEcCtD
Nilutamide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000268	0.0022	CcSEcCtD
Nilutamide—Dry skin—Epirubicin—uterine cancer	0.000266	0.00219	CcSEcCtD
Nilutamide—Chest pain—Etoposide—uterine cancer	0.000265	0.00218	CcSEcCtD
Nilutamide—Discomfort—Etoposide—uterine cancer	0.000262	0.00215	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000261	0.00215	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000256	0.0021	CcSEcCtD
Nilutamide—Asthenia—Dactinomycin—uterine cancer	0.000252	0.00207	CcSEcCtD
Nilutamide—Blood creatinine increased—Doxorubicin—uterine cancer	0.000251	0.00207	CcSEcCtD
Nilutamide—Influenza—Epirubicin—uterine cancer	0.000251	0.00206	CcSEcCtD
Nilutamide—Dry skin—Doxorubicin—uterine cancer	0.000246	0.00202	CcSEcCtD
Nilutamide—Hyperhidrosis—Etoposide—uterine cancer	0.000246	0.00202	CcSEcCtD
Nilutamide—Angina pectoris—Epirubicin—uterine cancer	0.000244	0.00201	CcSEcCtD
Nilutamide—Anorexia—Etoposide—uterine cancer	0.000242	0.00199	CcSEcCtD
Nilutamide—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.000242	0.00199	CcSEcCtD
Nilutamide—Diarrhoea—Dactinomycin—uterine cancer	0.00024	0.00198	CcSEcCtD
Nilutamide—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000237	0.00195	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Epirubicin—uterine cancer	0.000233	0.00192	CcSEcCtD
Nilutamide—Influenza—Doxorubicin—uterine cancer	0.000232	0.00191	CcSEcCtD
Nilutamide—Paraesthesia—Etoposide—uterine cancer	0.000228	0.00188	CcSEcCtD
Nilutamide—Weight decreased—Epirubicin—uterine cancer	0.000227	0.00186	CcSEcCtD
Nilutamide—Dyspnoea—Etoposide—uterine cancer	0.000227	0.00186	CcSEcCtD
Nilutamide—Hyperglycaemia—Epirubicin—uterine cancer	0.000226	0.00186	CcSEcCtD
Nilutamide—Angina pectoris—Doxorubicin—uterine cancer	0.000226	0.00186	CcSEcCtD
Nilutamide—Pneumonia—Epirubicin—uterine cancer	0.000225	0.00185	CcSEcCtD
Nilutamide—Vomiting—Dactinomycin—uterine cancer	0.000223	0.00184	CcSEcCtD
Nilutamide—AR—Nuclear Receptors—ESR1—uterine cancer	0.000222	0.0135	CbGpPWpGaD
Nilutamide—Rash—Dactinomycin—uterine cancer	0.000222	0.00182	CcSEcCtD
Nilutamide—Decreased appetite—Etoposide—uterine cancer	0.000221	0.00182	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Etoposide—uterine cancer	0.00022	0.0018	CcSEcCtD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—YWHAE—uterine cancer	0.000218	0.0133	CbGpPWpGaD
Nilutamide—Constipation—Etoposide—uterine cancer	0.000218	0.00179	CcSEcCtD
Nilutamide—Pain—Etoposide—uterine cancer	0.000218	0.00179	CcSEcCtD
Nilutamide—Urinary tract infection—Epirubicin—uterine cancer	0.000217	0.00179	CcSEcCtD
Nilutamide—Upper respiratory tract infection—Doxorubicin—uterine cancer	0.000216	0.00177	CcSEcCtD
Nilutamide—Sweating—Epirubicin—uterine cancer	0.000214	0.00176	CcSEcCtD
Nilutamide—Haematuria—Epirubicin—uterine cancer	0.000213	0.00175	CcSEcCtD
Nilutamide—Weight decreased—Doxorubicin—uterine cancer	0.00021	0.00172	CcSEcCtD
Nilutamide—Feeling abnormal—Etoposide—uterine cancer	0.00021	0.00172	CcSEcCtD
Nilutamide—Hyperglycaemia—Doxorubicin—uterine cancer	0.000209	0.00172	CcSEcCtD
Nilutamide—Nausea—Dactinomycin—uterine cancer	0.000209	0.00172	CcSEcCtD
Nilutamide—Pneumonia—Doxorubicin—uterine cancer	0.000208	0.00171	CcSEcCtD
Nilutamide—Gastrointestinal pain—Etoposide—uterine cancer	0.000208	0.00171	CcSEcCtD
Nilutamide—Rhinitis—Epirubicin—uterine cancer	0.000201	0.00165	CcSEcCtD
Nilutamide—Body temperature increased—Etoposide—uterine cancer	0.000201	0.00165	CcSEcCtD
Nilutamide—Abdominal pain—Etoposide—uterine cancer	0.000201	0.00165	CcSEcCtD
Nilutamide—Urinary tract infection—Doxorubicin—uterine cancer	0.000201	0.00165	CcSEcCtD
Nilutamide—Hypoaesthesia—Epirubicin—uterine cancer	0.0002	0.00164	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—MSH6—uterine cancer	0.000199	0.0121	CbGpPWpGaD
Nilutamide—Sweating—Doxorubicin—uterine cancer	0.000198	0.00163	CcSEcCtD
Nilutamide—Urinary tract disorder—Epirubicin—uterine cancer	0.000198	0.00163	CcSEcCtD
Nilutamide—Oedema peripheral—Epirubicin—uterine cancer	0.000198	0.00162	CcSEcCtD
Nilutamide—Haematuria—Doxorubicin—uterine cancer	0.000197	0.00162	CcSEcCtD
Nilutamide—AR—FOXA1 transcription factor network—ESR1—uterine cancer	0.000197	0.012	CbGpPWpGaD
Nilutamide—Urethral disorder—Epirubicin—uterine cancer	0.000197	0.00162	CcSEcCtD
Nilutamide—Visual impairment—Epirubicin—uterine cancer	0.000193	0.00159	CcSEcCtD
Nilutamide—Rhinitis—Doxorubicin—uterine cancer	0.000186	0.00153	CcSEcCtD
Nilutamide—Hypoaesthesia—Doxorubicin—uterine cancer	0.000185	0.00152	CcSEcCtD
Nilutamide—Urinary tract disorder—Doxorubicin—uterine cancer	0.000183	0.00151	CcSEcCtD
Nilutamide—Oedema peripheral—Doxorubicin—uterine cancer	0.000183	0.0015	CcSEcCtD
Nilutamide—Asthenia—Etoposide—uterine cancer	0.000182	0.0015	CcSEcCtD
Nilutamide—Urethral disorder—Doxorubicin—uterine cancer	0.000182	0.0015	CcSEcCtD
Nilutamide—Pruritus—Etoposide—uterine cancer	0.00018	0.00148	CcSEcCtD
Nilutamide—Visual impairment—Doxorubicin—uterine cancer	0.000179	0.00147	CcSEcCtD
Nilutamide—Alopecia—Epirubicin—uterine cancer	0.000177	0.00146	CcSEcCtD
Nilutamide—AR—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.000175	0.0107	CbGpPWpGaD
Nilutamide—Diarrhoea—Etoposide—uterine cancer	0.000174	0.00143	CcSEcCtD
Nilutamide—Tension—Epirubicin—uterine cancer	0.000171	0.00141	CcSEcCtD
Nilutamide—Nervousness—Epirubicin—uterine cancer	0.00017	0.00139	CcSEcCtD
Nilutamide—Back pain—Epirubicin—uterine cancer	0.000169	0.00139	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000169	0.0103	CbGpPWpGaD
Nilutamide—Dizziness—Etoposide—uterine cancer	0.000168	0.00138	CcSEcCtD
Nilutamide—Alopecia—Doxorubicin—uterine cancer	0.000164	0.00135	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDKN2B—uterine cancer	0.000162	0.00989	CbGpPWpGaD
Nilutamide—Ill-defined disorder—Epirubicin—uterine cancer	0.000162	0.00133	CcSEcCtD
Nilutamide—Vomiting—Etoposide—uterine cancer	0.000162	0.00133	CcSEcCtD
Nilutamide—Anaemia—Epirubicin—uterine cancer	0.000161	0.00133	CcSEcCtD
Nilutamide—AR—Integrated Breast Cancer Pathway—MSH2—uterine cancer	0.000161	0.00981	CbGpPWpGaD
Nilutamide—Rash—Etoposide—uterine cancer	0.00016	0.00132	CcSEcCtD
Nilutamide—Dermatitis—Etoposide—uterine cancer	0.00016	0.00132	CcSEcCtD
Nilutamide—CYP2C8—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.00016	0.00974	CbGpPWpGaD
Nilutamide—Headache—Etoposide—uterine cancer	0.000159	0.00131	CcSEcCtD
Nilutamide—Tension—Doxorubicin—uterine cancer	0.000159	0.0013	CcSEcCtD
Nilutamide—Malaise—Epirubicin—uterine cancer	0.000158	0.00129	CcSEcCtD
Nilutamide—Nervousness—Doxorubicin—uterine cancer	0.000157	0.00129	CcSEcCtD
Nilutamide—Syncope—Epirubicin—uterine cancer	0.000157	0.00129	CcSEcCtD
Nilutamide—Leukopenia—Epirubicin—uterine cancer	0.000156	0.00129	CcSEcCtD
Nilutamide—Back pain—Doxorubicin—uterine cancer	0.000156	0.00129	CcSEcCtD
Nilutamide—Loss of consciousness—Epirubicin—uterine cancer	0.000154	0.00126	CcSEcCtD
Nilutamide—Cough—Epirubicin—uterine cancer	0.000152	0.00125	CcSEcCtD
Nilutamide—Nausea—Etoposide—uterine cancer	0.000151	0.00124	CcSEcCtD
Nilutamide—Hypertension—Epirubicin—uterine cancer	0.000151	0.00124	CcSEcCtD
Nilutamide—Ill-defined disorder—Doxorubicin—uterine cancer	0.00015	0.00123	CcSEcCtD
Nilutamide—Anaemia—Doxorubicin—uterine cancer	0.000149	0.00123	CcSEcCtD
Nilutamide—Chest pain—Epirubicin—uterine cancer	0.000149	0.00122	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—SMAD3—uterine cancer	0.000148	0.00903	CbGpPWpGaD
Nilutamide—Discomfort—Epirubicin—uterine cancer	0.000147	0.00121	CcSEcCtD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000146	0.00892	CbGpPWpGaD
Nilutamide—Malaise—Doxorubicin—uterine cancer	0.000146	0.0012	CcSEcCtD
Nilutamide—Dry mouth—Epirubicin—uterine cancer	0.000145	0.0012	CcSEcCtD
Nilutamide—Syncope—Doxorubicin—uterine cancer	0.000145	0.00119	CcSEcCtD
Nilutamide—Leukopenia—Doxorubicin—uterine cancer	0.000145	0.00119	CcSEcCtD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000145	0.0088	CbGpPWpGaD
Nilutamide—CYP2C19—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000143	0.0087	CbGpPWpGaD
Nilutamide—Oedema—Epirubicin—uterine cancer	0.000143	0.00117	CcSEcCtD
Nilutamide—Loss of consciousness—Doxorubicin—uterine cancer	0.000142	0.00117	CcSEcCtD
Nilutamide—Cough—Doxorubicin—uterine cancer	0.000141	0.00116	CcSEcCtD
Nilutamide—Shock—Epirubicin—uterine cancer	0.00014	0.00115	CcSEcCtD
Nilutamide—Hypertension—Doxorubicin—uterine cancer	0.00014	0.00115	CcSEcCtD
Nilutamide—Hyperhidrosis—Epirubicin—uterine cancer	0.000138	0.00113	CcSEcCtD
Nilutamide—Chest pain—Doxorubicin—uterine cancer	0.000138	0.00113	CcSEcCtD
Nilutamide—AR—Androgen receptor signaling pathway—SMAD3—uterine cancer	0.000138	0.00837	CbGpPWpGaD
Nilutamide—Discomfort—Doxorubicin—uterine cancer	0.000136	0.00112	CcSEcCtD
Nilutamide—Anorexia—Epirubicin—uterine cancer	0.000136	0.00112	CcSEcCtD
Nilutamide—Dry mouth—Doxorubicin—uterine cancer	0.000135	0.00111	CcSEcCtD
Nilutamide—AR—FOXA1 transcription factor network—CDKN1B—uterine cancer	0.000134	0.00816	CbGpPWpGaD
Nilutamide—Oedema—Doxorubicin—uterine cancer	0.000132	0.00108	CcSEcCtD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000131	0.00796	CbGpPWpGaD
Nilutamide—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.00013	0.00793	CbGpPWpGaD
Nilutamide—Shock—Doxorubicin—uterine cancer	0.00013	0.00107	CcSEcCtD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000129	0.00785	CbGpPWpGaD
Nilutamide—Insomnia—Epirubicin—uterine cancer	0.000129	0.00106	CcSEcCtD
Nilutamide—Paraesthesia—Epirubicin—uterine cancer	0.000128	0.00105	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—YWHAE—uterine cancer	0.000128	0.00779	CbGpPWpGaD
Nilutamide—Hyperhidrosis—Doxorubicin—uterine cancer	0.000128	0.00105	CcSEcCtD
Nilutamide—AR—Notch-mediated HES/HEY network—CDKN1B—uterine cancer	0.000127	0.00774	CbGpPWpGaD
Nilutamide—Dyspnoea—Epirubicin—uterine cancer	0.000127	0.00104	CcSEcCtD
Nilutamide—Anorexia—Doxorubicin—uterine cancer	0.000126	0.00103	CcSEcCtD
Nilutamide—Dyspepsia—Epirubicin—uterine cancer	0.000126	0.00103	CcSEcCtD
Nilutamide—Decreased appetite—Epirubicin—uterine cancer	0.000124	0.00102	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000123	0.00101	CcSEcCtD
Nilutamide—Constipation—Epirubicin—uterine cancer	0.000122	0.001	CcSEcCtD
Nilutamide—Pain—Epirubicin—uterine cancer	0.000122	0.001	CcSEcCtD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—uterine cancer	0.000121	0.00737	CbGpPWpGaD
Nilutamide—Insomnia—Doxorubicin—uterine cancer	0.000119	0.000981	CcSEcCtD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	0.000119	0.00726	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000119	0.00723	CbGpPWpGaD
Nilutamide—Paraesthesia—Doxorubicin—uterine cancer	0.000118	0.000974	CcSEcCtD
Nilutamide—AR—SIDS Susceptibility Pathways—ESR2—uterine cancer	0.000118	0.00719	CbGpPWpGaD
Nilutamide—AR—FOXA1 transcription factor network—EP300—uterine cancer	0.000118	0.00716	CbGpPWpGaD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	0.000118	0.00716	CbGpPWpGaD
Nilutamide—Dyspnoea—Doxorubicin—uterine cancer	0.000118	0.000967	CcSEcCtD
Nilutamide—Feeling abnormal—Epirubicin—uterine cancer	0.000117	0.000966	CcSEcCtD
Nilutamide—Gastrointestinal pain—Epirubicin—uterine cancer	0.000117	0.000958	CcSEcCtD
Nilutamide—AR—Coregulation of Androgen receptor activity—CDKN2A—uterine cancer	0.000117	0.00709	CbGpPWpGaD
Nilutamide—Dyspepsia—Doxorubicin—uterine cancer	0.000116	0.000954	CcSEcCtD
Nilutamide—AR—Nongenotropic Androgen signaling—PIK3CA—uterine cancer	0.000115	0.00701	CbGpPWpGaD
Nilutamide—Decreased appetite—Doxorubicin—uterine cancer	0.000115	0.000943	CcSEcCtD
Nilutamide—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000114	0.000936	CcSEcCtD
Nilutamide—Constipation—Doxorubicin—uterine cancer	0.000113	0.000927	CcSEcCtD
Nilutamide—Pain—Doxorubicin—uterine cancer	0.000113	0.000927	CcSEcCtD
Nilutamide—Abdominal pain—Epirubicin—uterine cancer	0.000113	0.000926	CcSEcCtD
Nilutamide—Body temperature increased—Epirubicin—uterine cancer	0.000113	0.000926	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—AKR1B10—uterine cancer	0.000112	0.00681	CbGpPWpGaD
Nilutamide—AR—Notch-mediated HES/HEY network—EP300—uterine cancer	0.000112	0.0068	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—STK11—uterine cancer	0.00011	0.0067	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CYP19A1—uterine cancer	0.00011	0.0067	CbGpPWpGaD
Nilutamide—Feeling abnormal—Doxorubicin—uterine cancer	0.000109	0.000893	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	0.000108	0.0066	CbGpPWpGaD
Nilutamide—Gastrointestinal pain—Doxorubicin—uterine cancer	0.000108	0.000887	CcSEcCtD
Nilutamide—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	0.000108	0.00656	CbGpPWpGaD
Nilutamide—AR—Nongenotropic Androgen signaling—HRAS—uterine cancer	0.000107	0.00649	CbGpPWpGaD
Nilutamide—CYP2C8—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	0.000106	0.00647	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—uterine cancer	0.000106	0.00647	CbGpPWpGaD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	0.000106	0.00645	CbGpPWpGaD
Nilutamide—Abdominal pain—Doxorubicin—uterine cancer	0.000104	0.000857	CcSEcCtD
Nilutamide—Body temperature increased—Doxorubicin—uterine cancer	0.000104	0.000857	CcSEcCtD
Nilutamide—CYP2C8—Metapathway biotransformation—AKR1B1—uterine cancer	0.000104	0.00633	CbGpPWpGaD
Nilutamide—Asthenia—Epirubicin—uterine cancer	0.000102	0.000841	CcSEcCtD
Nilutamide—AR—Regulation of Androgen receptor activity—EP300—uterine cancer	0.000101	0.00617	CbGpPWpGaD
Nilutamide—Pruritus—Epirubicin—uterine cancer	0.000101	0.000829	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	0.0001	0.00611	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—AKR1B10—uterine cancer	9.98e-05	0.00608	CbGpPWpGaD
Nilutamide—Diarrhoea—Epirubicin—uterine cancer	9.76e-05	0.000802	CcSEcCtD
Nilutamide—AR—Coregulation of Androgen receptor activity—CTNNB1—uterine cancer	9.75e-05	0.00593	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	9.66e-05	0.00588	CbGpPWpGaD
Nilutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	9.62e-05	0.00585	CbGpPWpGaD
Nilutamide—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	9.49e-05	0.00578	CbGpPWpGaD
Nilutamide—Asthenia—Doxorubicin—uterine cancer	9.47e-05	0.000778	CcSEcCtD
Nilutamide—Dizziness—Epirubicin—uterine cancer	9.43e-05	0.000775	CcSEcCtD
Nilutamide—AR—Nongenotropic Androgen signaling—AKT1—uterine cancer	9.41e-05	0.00573	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—uterine cancer	9.38e-05	0.00571	CbGpPWpGaD
Nilutamide—Pruritus—Doxorubicin—uterine cancer	9.33e-05	0.000767	CcSEcCtD
Nilutamide—CYP2C19—Metapathway biotransformation—AKR1B1—uterine cancer	9.28e-05	0.00565	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	9.12e-05	0.00555	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	9.1e-05	0.00554	CbGpPWpGaD
Nilutamide—Vomiting—Epirubicin—uterine cancer	9.07e-05	0.000745	CcSEcCtD
Nilutamide—Diarrhoea—Doxorubicin—uterine cancer	9.03e-05	0.000742	CcSEcCtD
Nilutamide—Rash—Epirubicin—uterine cancer	8.99e-05	0.000739	CcSEcCtD
Nilutamide—Dermatitis—Epirubicin—uterine cancer	8.98e-05	0.000738	CcSEcCtD
Nilutamide—Headache—Epirubicin—uterine cancer	8.93e-05	0.000734	CcSEcCtD
Nilutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	8.77e-05	0.00534	CbGpPWpGaD
Nilutamide—CYP2C8—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	8.74e-05	0.00532	CbGpPWpGaD
Nilutamide—Dizziness—Doxorubicin—uterine cancer	8.72e-05	0.000717	CcSEcCtD
Nilutamide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	8.66e-05	0.00527	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—uterine cancer	8.51e-05	0.00518	CbGpPWpGaD
Nilutamide—Nausea—Epirubicin—uterine cancer	8.47e-05	0.000696	CcSEcCtD
Nilutamide—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	8.46e-05	0.00515	CbGpPWpGaD
Nilutamide—Vomiting—Doxorubicin—uterine cancer	8.39e-05	0.000689	CcSEcCtD
Nilutamide—Rash—Doxorubicin—uterine cancer	8.32e-05	0.000684	CcSEcCtD
Nilutamide—Dermatitis—Doxorubicin—uterine cancer	8.31e-05	0.000683	CcSEcCtD
Nilutamide—Headache—Doxorubicin—uterine cancer	8.26e-05	0.000679	CcSEcCtD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	8.18e-05	0.00498	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—uterine cancer	7.85e-05	0.00478	CbGpPWpGaD
Nilutamide—Nausea—Doxorubicin—uterine cancer	7.84e-05	0.000644	CcSEcCtD
Nilutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	7.8e-05	0.00475	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PHF1—uterine cancer	7.69e-05	0.00468	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—AKR1C1—uterine cancer	7.63e-05	0.00464	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—ESR1—uterine cancer	7.35e-05	0.00448	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—uterine cancer	7.3e-05	0.00444	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—EP300—uterine cancer	7.22e-05	0.0044	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—CTNNB1—uterine cancer	7.21e-05	0.00439	CbGpPWpGaD
Nilutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	7.11e-05	0.00433	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—PTEN—uterine cancer	7.02e-05	0.00428	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—AKR1C1—uterine cancer	6.81e-05	0.00415	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—GPX3—uterine cancer	6.7e-05	0.00408	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—EP300—uterine cancer	6.7e-05	0.00408	CbGpPWpGaD
Nilutamide—AR—Gene Expression—CHD4—uterine cancer	6.54e-05	0.00398	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CDH1—uterine cancer	6.4e-05	0.00389	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP11A1—uterine cancer	6.31e-05	0.00384	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP11A1—uterine cancer	6.22e-05	0.00379	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	6.21e-05	0.00378	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	6.09e-05	0.00371	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	5.98e-05	0.00364	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—AKR1C3—uterine cancer	5.87e-05	0.00358	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—PGR—uterine cancer	5.67e-05	0.00345	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	5.63e-05	0.00343	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	5.6e-05	0.00341	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	5.55e-05	0.00338	CbGpPWpGaD
Nilutamide—AR—Gene Expression—SUZ12—uterine cancer	5.48e-05	0.00334	CbGpPWpGaD
Nilutamide—AR—Coregulation of Androgen receptor activity—AKT1—uterine cancer	5.48e-05	0.00333	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	5.45e-05	0.00332	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	5.24e-05	0.00319	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	5.13e-05	0.00312	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	5.06e-05	0.00308	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	5e-05	0.00304	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—ESR2—uterine cancer	4.99e-05	0.00304	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CXCL8—uterine cancer	4.99e-05	0.00303	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	4.78e-05	0.00291	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	4.72e-05	0.00287	CbGpPWpGaD
Nilutamide—CYP2C8—Biological oxidations—CYP19A1—uterine cancer	4.64e-05	0.00282	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—PTEN—uterine cancer	4.6e-05	0.0028	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	4.6e-05	0.0028	CbGpPWpGaD
Nilutamide—CYP2C8—Metapathway biotransformation—CYP19A1—uterine cancer	4.58e-05	0.00279	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	4.56e-05	0.00277	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	4.47e-05	0.00272	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—EP300—uterine cancer	4.39e-05	0.00267	CbGpPWpGaD
Nilutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	4.37e-05	0.00266	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—EP300—uterine cancer	4.28e-05	0.0026	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	4.16e-05	0.00253	CbGpPWpGaD
Nilutamide—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	4.14e-05	0.00252	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	4.14e-05	0.00252	CbGpPWpGaD
Nilutamide—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	4.09e-05	0.00249	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—CDKN2B—uterine cancer	4.06e-05	0.00247	CbGpPWpGaD
Nilutamide—AR—SIDS Susceptibility Pathways—VEGFA—uterine cancer	4.05e-05	0.00246	CbGpPWpGaD
Nilutamide—AR—Androgen receptor signaling pathway—AKT1—uterine cancer	4.05e-05	0.00246	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	4.05e-05	0.00246	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—STAR—uterine cancer	4.05e-05	0.00246	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	3.91e-05	0.00238	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	3.81e-05	0.00232	CbGpPWpGaD
Nilutamide—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	3.78e-05	0.0023	CbGpPWpGaD
Nilutamide—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	3.73e-05	0.00227	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—SMAD3—uterine cancer	3.71e-05	0.00226	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	3.64e-05	0.00221	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	3.61e-05	0.0022	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	3.61e-05	0.0022	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—KRAS—uterine cancer	3.53e-05	0.00215	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	3.44e-05	0.0021	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	3.29e-05	0.00201	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	3.29e-05	0.00201	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—TP53—uterine cancer	3.14e-05	0.00191	CbGpPWpGaD
Nilutamide—AR—Generic Transcription Pathway—ESR1—uterine cancer	3.03e-05	0.00184	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.97e-05	0.00181	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.93e-05	0.00178	CbGpPWpGaD
Nilutamide—AR—Gene Expression—PGR—uterine cancer	2.73e-05	0.00166	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	2.69e-05	0.00164	CbGpPWpGaD
Nilutamide—AR—Integrated Breast Cancer Pathway—AKT1—uterine cancer	2.65e-05	0.00161	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.65e-05	0.00161	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	2.6e-05	0.00158	CbGpPWpGaD
Nilutamide—AR—Gene Expression—EZH2—uterine cancer	2.59e-05	0.00158	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—SRD5A2—uterine cancer	2.49e-05	0.00152	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—NDUFB11—uterine cancer	2.49e-05	0.00152	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.42e-05	0.00147	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	2.42e-05	0.00147	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ESR2—uterine cancer	2.4e-05	0.00146	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.29e-05	0.00139	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—NDUFB11—uterine cancer	2.23e-05	0.00135	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—SRD5A2—uterine cancer	2.23e-05	0.00135	CbGpPWpGaD
Nilutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	2.2e-05	0.00134	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	2.16e-05	0.00132	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	2.04e-05	0.00124	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—SRD5A2—uterine cancer	2.03e-05	0.00124	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—NDUFB11—uterine cancer	2.03e-05	0.00124	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.97e-05	0.0012	CbGpPWpGaD
Nilutamide—AR—Gene Expression—CDKN2B—uterine cancer	1.96e-05	0.00119	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.86e-05	0.00113	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKR1B1—uterine cancer	1.8e-05	0.0011	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—STAR—uterine cancer	1.8e-05	0.0011	CbGpPWpGaD
Nilutamide—AR—Gene Expression—SMAD3—uterine cancer	1.79e-05	0.00109	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.78e-05	0.00108	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKR1B1—uterine cancer	1.61e-05	0.000979	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—STAR—uterine cancer	1.61e-05	0.000979	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.59e-05	0.000968	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.47e-05	0.000893	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—STAR—uterine cancer	1.47e-05	0.000893	CbGpPWpGaD
Nilutamide—AR—Gene Expression—ESR1—uterine cancer	1.46e-05	0.000887	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.45e-05	0.000883	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—POLD1—uterine cancer	1.41e-05	0.000861	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKR1C1—uterine cancer	1.32e-05	0.000805	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—POLD1—uterine cancer	1.26e-05	0.000769	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKR1C1—uterine cancer	1.18e-05	0.000719	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—RRM2—uterine cancer	1.18e-05	0.000718	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—POLD1—uterine cancer	1.15e-05	0.000701	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—DCN—uterine cancer	1.14e-05	0.000697	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP11A1—uterine cancer	1.08e-05	0.000657	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKR1C1—uterine cancer	1.08e-05	0.000655	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—RRM2—uterine cancer	1.05e-05	0.000641	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—DCN—uterine cancer	1.02e-05	0.000622	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKR1C3—uterine cancer	1.02e-05	0.00062	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP11A1—uterine cancer	9.63e-06	0.000586	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—RRM2—uterine cancer	9.6e-06	0.000584	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—DCN—uterine cancer	9.32e-06	0.000567	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKR1C3—uterine cancer	9.09e-06	0.000553	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP11A1—uterine cancer	8.78e-06	0.000534	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKR1C3—uterine cancer	8.29e-06	0.000505	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—STK11—uterine cancer	7.94e-06	0.000483	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—CYP19A1—uterine cancer	7.94e-06	0.000483	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.45e-06	0.000453	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	7.1e-06	0.000432	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—CYP19A1—uterine cancer	7.08e-06	0.000431	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—STK11—uterine cancer	7.08e-06	0.000431	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.65e-06	0.000405	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—STK11—uterine cancer	6.46e-06	0.000393	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—CYP19A1—uterine cancer	6.46e-06	0.000393	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.34e-06	0.000386	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.06e-06	0.000369	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—MTHFR—uterine cancer	5.96e-06	0.000363	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.78e-06	0.000352	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—MTHFR—uterine cancer	5.32e-06	0.000324	CbGpPWpGaD
Nilutamide—AR—Gene Expression—AKT1—uterine cancer	5.26e-06	0.00032	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.26e-06	0.00032	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—MTHFR—uterine cancer	4.85e-06	0.000295	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.69e-06	0.000286	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.28e-06	0.00026	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PTEN—uterine cancer	3.32e-06	0.000202	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—EP300—uterine cancer	3.16e-06	0.000193	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PTEN—uterine cancer	2.96e-06	0.00018	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—EP300—uterine cancer	2.82e-06	0.000172	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PTEN—uterine cancer	2.7e-06	0.000164	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—EP300—uterine cancer	2.58e-06	0.000157	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—PIK3CA—uterine cancer	2.34e-06	0.000142	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—PIK3CA—uterine cancer	2.09e-06	0.000127	CbGpPWpGaD
Nilutamide—CYP2C8—Metabolism—AKT1—uterine cancer	1.91e-06	0.000116	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.9e-06	0.000116	CbGpPWpGaD
Nilutamide—CYP2C19—Metabolism—AKT1—uterine cancer	1.71e-06	0.000104	CbGpPWpGaD
Nilutamide—CYP2C9—Metabolism—AKT1—uterine cancer	1.56e-06	9.47e-05	CbGpPWpGaD
